Literature DB >> 11728409

Some ethical and design challenges of screening programs and screening tests.

Matthew J McQueen1.   

Abstract

BACKGROUND: There are many examples of inadequate screening studies because of design faults and consent problems. ISSUES: Informed consent is the right of each person engaged in a clinical interaction, including service and research involvement in presymptomatic screening. Any screening approach must answer questions of efficacy, effectiveness, availability and efficiency. Accurate information, presented in clear language, must state a realistic assessment of the limitations, harms and benefits of the screening, including the consequences of false positive and false negative tests. There must be no coercive element in obtaining consent. Written and oral information should be presented. It is also important to recognize cultural differences between societies that emphasize individual autonomy and those in which autonomy derives from membership of a family, group or community, thus requiring different strategies to protect the vulnerable. Testing for genetic disorders presents additional challenges, partly due to the presence of relatively small numbers of affected individuals in the population, but also because of the complexity of counseling, confidentiality issues and the potential for social, insurance or employment discrimination.
CONCLUSIONS: It is becoming increasingly difficult to present the data for many screening procedures in ways that can be understood by possible participants, and at the same time deal clearly with the costs to society and the efficacy and efficiency of the tests.

Entities:  

Mesh:

Year:  2002        PMID: 11728409     DOI: 10.1016/s0009-8981(01)00719-7

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  8 in total

1.  Parental consent for newborn screening in southern Taiwan.

Authors:  M-C Huang; C-K Lee; S-J Lin; I-C Lu
Journal:  J Med Ethics       Date:  2005-11       Impact factor: 2.903

2.  Attitudes of health care professionals toward carrier screening for cystic fibrosis. A review of the literature.

Authors:  S Janssens; A De Paepe; P Borry
Journal:  J Community Genet       Date:  2012-12-29

3.  Outcome and survival of 88 patients with urea cycle disorders: a retrospective evaluation.

Authors:  Claude Bachmann
Journal:  Eur J Pediatr       Date:  2003-03-27       Impact factor: 3.183

4.  Preconceptional ancestry-based carrier couple screening for cystic fibrosis and haemoglobinopathies: what determines the intention to participate or not and actual participation?

Authors:  Phillis Lakeman; Anne Marie Catharina Plass; Lidewij Henneman; Pieter Dirk Bezemer; Martina Cornelia Cornel; Leo Pieter ten Kate
Journal:  Eur J Hum Genet       Date:  2009-02-18       Impact factor: 4.246

5.  Preconceptional genetic carrier testing and the commercial offer directly-to-consumers.

Authors:  Pascal Borry; Lidewij Henneman; Phillis Lakeman; Leo P ten Kate; Martina C Cornel; Heidi C Howard
Journal:  Hum Reprod       Date:  2011-02-28       Impact factor: 6.918

Review 6.  Screening tests: a review with examples.

Authors:  L Daniel Maxim; Ron Niebo; Mark J Utell
Journal:  Inhal Toxicol       Date:  2014-09-29       Impact factor: 2.724

7.  Are good intentions good enough? Informed consent without trained interpreters.

Authors:  Linda M Hunt; Katherine B de Voogd
Journal:  J Gen Intern Med       Date:  2007-03-02       Impact factor: 5.128

8.  Ethical issues in preconception genetic carrier screening.

Authors:  Ulrik Kihlbom
Journal:  Ups J Med Sci       Date:  2016-07-08       Impact factor: 2.384

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.